195 related articles for article (PubMed ID: 37647503)
1. Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
Hirano T; Hayashi T; Sugita H; Tamasawa A; Goto S; Tomoyasu M; Yamamoto T; Ohara M; Terasaki M; Kushima H; Ito Y; Yamagishi SI; Mori Y
J Diabetes Investig; 2023 Dec; 14(12):1401-1411. PubMed ID: 37647503
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol.
Hirano T; Kodera R; Hirashima T; Suzuki N; Aoki E; Hosoya M; Oshima T; Hayashi T; Koba S; Ohta M; Satoh N; Ito Y
J Atheroscler Thromb; 2022 May; 29(5):762-774. PubMed ID: 33952832
[TBL] [Abstract][Full Text] [Related]
4. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
Komiya I; Yamamoto A; Sunakawa S; Wakugami T
Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
[TBL] [Abstract][Full Text] [Related]
5. Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment.
Yamaji T; Harada T; Kajikawa M; Maruhashi T; Kishimoto S; Yusoff FM; Chayama K; Goto C; Nakashima A; Tomiyama H; Takase B; Kohro T; Suzuki T; Ishizu T; Ueda S; Yamazaki T; Furumoto T; Kario K; Inoue T; Watanabe K; Takemoto Y; Hano T; Sata M; Ishibashi Y; Node K; Maemura K; Ohya Y; Furukawa T; Ito H; Yamashina A; Koba S; Higashi Y
J Atheroscler Thromb; 2024 Apr; 31(4):478-500. PubMed ID: 37926523
[TBL] [Abstract][Full Text] [Related]
6. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
[TBL] [Abstract][Full Text] [Related]
7. The influence of triglycerides on small dense low-density lipoprotein cholesterol levels is attenuated in low low-density lipoprotein-cholesterol range: Implications for the negative results of the PROMINENT trial.
Hirano T; Ito Y
J Diabetes Investig; 2023 Jul; 14(7):902-906. PubMed ID: 37016542
[TBL] [Abstract][Full Text] [Related]
8. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Small Dense Low-density Lipoprotein-cholesterol Concentration Estimated via Sampson's Equation in Healthy Subjects and Patients with Diabetes.
Hirano T; Ito Y
J Atheroscler Thromb; 2023 Aug; 30(8):979-989. PubMed ID: 36216531
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
Atherosclerosis; 2017 Jun; 261():144-152. PubMed ID: 28410749
[TBL] [Abstract][Full Text] [Related]
12. Comparison of statins in hypertriglyceridemia.
Stein EA; Lane M; Laskarzewski P
Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
14. Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease.
Ishii J; Kashiwabara K; Ozaki Y; Takahashi H; Kitagawa F; Nishimura H; Ishii H; Iimuro S; Kawai H; Muramatsu T; Naruse H; Iwata H; Tanizawa-Motoyama S; Ito H; Watanabe E; Matsuyama Y; Fukumoto Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Hokimoto S; Miyauchi K; Ohtsu H; Izawa H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Matsuzaki M; Nagai R
J Atheroscler Thromb; 2022 Oct; 29(10):1458-1474. PubMed ID: 34880156
[TBL] [Abstract][Full Text] [Related]
15. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
Yu D; Murdoch SJ; Parikh SJ; Marcovina SM; Cobitz A; Chen H; Brunzell JD
Diab Vasc Dis Res; 2006 Dec; 3(3):189-96. PubMed ID: 17160915
[TBL] [Abstract][Full Text] [Related]
17. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
18. [Statin therapy for atherogenic hypertriglyceridemia].
Koba S
Nihon Rinsho; 2013 Sep; 71(9):1655-60. PubMed ID: 24205730
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan.
Hsu H; Hsu P; Cheng MH; Ito Y; Kanda E; Schaefer EJ; Ai M
J Atheroscler Thromb; 2019 Oct; 26(10):890-914. PubMed ID: 30726792
[TBL] [Abstract][Full Text] [Related]
20. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study.
Ikezaki H; Lim E; Cupples LA; Liu CT; Asztalos BF; Schaefer EJ
J Am Heart Assoc; 2021 Feb; 10(5):e019140. PubMed ID: 33586462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
